Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host targeting agents.
“Direct acting antivirals have significantly improved treatment outcomes in chronic hepatitis C (CHC), but side effects, drug resistance and cost mean that better treatments are still needed.
Lipid metabolism is closely linked with hepatitis C virus (HCV) replication and endocannabinoids are major regulators of lipid homeostasis.
The cannabinoid 1 (CB1) receptor mediates these effects in the liver.
Here we investigated whether CB1 blockade inhibits HCV replication.
The antiviral effect of a CB1 antagonist, AM251 was examined…
Treatment with AM251 strongly inhibited HCV RNA (~70%), viral protein (~80%), the production of new virus particles (~70%), and virus infectivity (~90%)…
We suggest that CB1 antagonists may represent an entirely new class of drugs with activity against HCV.
This Research and Resources page is sponsored by the Ohio Rights Group Education Fund.
Please support our charitable and educational work by making a generous tax deductible donation.